JP2010525056A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525056A5
JP2010525056A5 JP2010506133A JP2010506133A JP2010525056A5 JP 2010525056 A5 JP2010525056 A5 JP 2010525056A5 JP 2010506133 A JP2010506133 A JP 2010506133A JP 2010506133 A JP2010506133 A JP 2010506133A JP 2010525056 A5 JP2010525056 A5 JP 2010525056A5
Authority
JP
Japan
Prior art keywords
compound according
alkoxy
pharmaceutically acceptable
monosubstituted
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525056A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2008/050459 external-priority patent/WO2008130320A2/en
Publication of JP2010525056A publication Critical patent/JP2010525056A/ja
Publication of JP2010525056A5 publication Critical patent/JP2010525056A5/ja
Pending legal-status Critical Current

Links

JP2010506133A 2007-04-23 2008-04-22 新規化合物 Pending JP2010525056A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23
PCT/SE2008/050459 WO2008130320A2 (en) 2007-04-23 2008-04-22 Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2010525056A JP2010525056A (ja) 2010-07-22
JP2010525056A5 true JP2010525056A5 (cg-RX-API-DMAC10.html) 2012-06-07

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506133A Pending JP2010525056A (ja) 2007-04-23 2008-04-22 新規化合物

Country Status (23)

Country Link
US (2) US8143408B2 (cg-RX-API-DMAC10.html)
EP (1) EP2158198B1 (cg-RX-API-DMAC10.html)
JP (1) JP2010525056A (cg-RX-API-DMAC10.html)
KR (1) KR20100015827A (cg-RX-API-DMAC10.html)
CN (1) CN101687860B (cg-RX-API-DMAC10.html)
AR (1) AR066266A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008241610B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0810354A2 (cg-RX-API-DMAC10.html)
CA (1) CA2685141A1 (cg-RX-API-DMAC10.html)
CL (1) CL2008001170A1 (cg-RX-API-DMAC10.html)
CO (1) CO6251361A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP099706A (cg-RX-API-DMAC10.html)
IL (1) IL201309A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009011364A (cg-RX-API-DMAC10.html)
MY (1) MY146662A (cg-RX-API-DMAC10.html)
NZ (1) NZ581353A (cg-RX-API-DMAC10.html)
PE (1) PE20090727A1 (cg-RX-API-DMAC10.html)
RU (1) RU2460730C2 (cg-RX-API-DMAC10.html)
SA (1) SA08290245B1 (cg-RX-API-DMAC10.html)
TW (1) TW200848037A (cg-RX-API-DMAC10.html)
UY (1) UY31046A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008130320A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200907137B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8748623B2 (en) * 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
KR20120091240A (ko) * 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
EP2532656A1 (en) 2010-02-01 2012-12-12 Nippon Chemiphar Co., Ltd. Gpr119 agonist
JP6486002B2 (ja) * 2010-08-23 2019-03-20 シントリックス・バイオシステムズ・インコーポレイテッドSyntrix Biosystems, Inc. Cxcr2モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102603659B (zh) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
KR102226587B1 (ko) * 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
SG11201606367YA (en) * 2014-02-06 2016-09-29 Abbvie Inc 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
KR102245930B1 (ko) 2015-11-13 2021-04-29 주식회사 대웅제약 소디움 채널 차단제
CN105541774B (zh) * 2016-01-13 2018-06-15 华中师范大学 3,4-二氢香豆素类化合物及其制备方法和用途
PE20200608A1 (es) * 2017-06-30 2020-03-10 Bayer Animal Health Gmbh Nuevos derivados de azaquinolina
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2020005888A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
PL3851436T3 (pl) 2018-09-10 2024-12-16 Kaken Pharmaceutical Co., Ltd. Nowa heteroaromatyczna pochodna amidowa i lek ją zawierający
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CA3209557A1 (en) 2021-03-04 2022-09-09 Bradley P. Morgan Cardiac sarcomere inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (ja) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd アザクロマン誘導体及びその用途
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (ja) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd ポリフェノール化合物及びこれを含有する医薬
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7858786B2 (en) * 2005-05-04 2010-12-28 Vertex Pharmaceuticals Incoropated Pyrimidines and pyrazines useful as modulators of ion channels
WO2008008020A1 (en) * 2006-07-12 2008-01-17 Astrazeneca Ab 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم

Similar Documents

Publication Publication Date Title
JP2010525056A5 (cg-RX-API-DMAC10.html)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
JP2013542247A5 (cg-RX-API-DMAC10.html)
JP2014511891A5 (cg-RX-API-DMAC10.html)
JP2009514870A5 (cg-RX-API-DMAC10.html)
JP2013522326A5 (cg-RX-API-DMAC10.html)
JP2016040288A5 (cg-RX-API-DMAC10.html)
JP2015523397A5 (cg-RX-API-DMAC10.html)
JP2012041349A5 (cg-RX-API-DMAC10.html)
JP2014521735A5 (cg-RX-API-DMAC10.html)
JP2013544860A5 (cg-RX-API-DMAC10.html)
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
JP2015503596A5 (cg-RX-API-DMAC10.html)
JP2014508804A5 (cg-RX-API-DMAC10.html)
JP2014505107A5 (cg-RX-API-DMAC10.html)
JP2016531126A5 (cg-RX-API-DMAC10.html)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
RU2011153353A (ru) Кетолидные соединения, обладающие противомикробной активностью
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
TNSN07419A1 (en) Methods for treating drug resistant cancer
JP2017529389A5 (cg-RX-API-DMAC10.html)
JP2015536974A5 (cg-RX-API-DMAC10.html)
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor